Stock OCUL OCULAR THERAPEUTIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Delayed Nasdaq
Other stock markets
 03:51:18 2024-05-15 pm EDT 		5-day change 1st Jan Change
6.375 USD +5.37% Intraday chart for Ocular Therapeutix, Inc. +10.61% +42.60%
May. 07 Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M MT
May. 07 Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
AQ
Ocular Therapeutix: Q1 Earnings Snapshot
AQ
Ocular Therapeutix™ Reports First Quarter 2024 Results
AQ
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Ocular Therapeutix to Present at Two Ophthalmology Meetings, May 4-9, 2024
AQ
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
AQ
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
AQ
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
AQ
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy
AQ
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K
PU
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
AQ
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
AQ
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
AQ
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
AQ
Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4) to Senior Vice President of Global Head of Biometrics
AQ
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
AQ
Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
AQ
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
AQ
Ocular Therapeutix to Present Data at the 2024 ASCRS Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCUL Stock
  4. News Ocular Therapeutix, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW